YourStory | Stories about भारत
YourStory.com is India’s biggest and definitive platform for startups and entrepreneurs related stories, resources, research reports and analysis of the startup eco-system, mobile app developers and more dedicated to promote the startup ecosystem
Black Friday Sale 2020: Top smartphone deals you don't want to miss - YourStory
Apple, Samsung, Xiaomi, and more — here are some steal deals you may not want to miss in ongoing Black Friday sale on various ecommerce platforms.
Its a deal season on ecommerce platforms like Amazon and Flipkart have kicked off 'Black Friday' sale this week. And, smartphones are in the spotlight of these deals, featuring Apple, Samsung, Xiaomi, and many more. Mi 10 5G Xiaomi is offering huge discounts on its latest smartphones. On Amazon, you can see that Xiaomi is offering Redmi Note 9 Pro at Rs 14,999 instead of Rs 17,999. And, Redmi 9 Prime, which packs a massive battery of 5,000 mAh, too is available for a discount of Rs 3,000. Xiaomi's premium phone Mi 10 5G has the best deal and is available at Rs 44,999 instead of Rs 54,999. Almost all the Xiaomi products have deep discounts and the Black Friday could help you to bag some steal deals, which can be bought on Amazon as well as Xiaomi's own website. Samsung Galaxy If you have been someone eying Samsung's Galaxy series, then Samsung Galaxy S20+, as well as the Galaxy Note 10+ has exchange offers with a discount of up to Rs 14,300. Besides this, on Flipkart's Black Friday sale, Samsung Galaxy A70's prices are slashed down by Rs 5,000, and one can buy the 6GB + 128GB variant for Rs 17,999, and 8GB RAM variant for Rs 25,999. Apple You might want to grab an iPhone this season as Flipkart is offering a huge discount of Rs 14,300. The iPhone XR is available for Rs 38,999 instead of Rs 47,900 for the 64GB version. The 128 GB variant of iPhone XR is also at a discount and can be bought for Rs 43,999 instead of Rs 52,900. Other Apple smartphone too are available on heavy discounts, and you might want to check out some on Flipkart. Realme realme's smartphones including realme 6i, realme 6, realme X3 Superzoom and X50 Pro, and various AIoT products such as realme Buds Classic, realme Smart Watch, realme Buds Air Neo and realme Smart Cam 360 are out there on discount as well. Around Rs 1,000 worth of discount will be applicable on realme C3, realme 6, realme 6i and narzo 20. And discounts worth Rs 3,000 and Rs 4,000 will be available on the realme X3 and realme X3 SuperZoom respectively, while the realme X50 Pro is available massive discount of Rs 7000. Buyers can bag these deals on Real's website as well as on Flipkart.
Explainer: Google Play commission structure and what Indian startups need to know - YourStory
Many Indian startups have raised concerns around Google Play Store’s billing system and are now thinking of an alternative app store to get the freedom to act independently.
The decision by tech giant Google to enforce 30 percent fee as commission for in-app purchases on its Play Store has sent shockwaves across the country, especially in the startup community, whose lifeline depends on these mobile applications. On one hand, Google is monetising its platform, which is overwhelmingly dominant, but enforcing 30 percent commission will be a huge burden for the Indian startup ecosystem. Considering the fact that digitisation has just started to make inroads in the Indian economy, the latest fee structure is perhaps a little too early for the country. This is also the time for the startup ecosystem, government, and other important stakeholders to think of an alternative app store, which will align with the government’s vision of ‘Aatmanirbhar Bharat’. A national app store with the freedom to act independently with the interests of startups in mind is the need of the hour. YourStory provides a picture about Google Play Store’s new commission structure and its key implications.
- Anybody can upload an app on the Google Play Store provided the guidelines are met.
- According to Google Play Store regulations, any app which provides digital goods or services can be charged 30 percent commission.
- This means any app which has a subscription feature on it, where consumers pay a fee, is liable to pay 30 percent commission.
- The type of apps which falls into this subscription category include gaming, news, OTT (Netflix, Spotify, Amazon Prime), music, dating, fitness, edtech, data storage, etc. Find the full list here.
- This commission does not apply for those apps which enable transaction of physical goods like ecommerce, food delivery, ticket buying services, transport services, online payment (Paytm, PhonePe). The list is here.
- The 30 percent commission has been operational since January, 2018, but was not strictly enforced.
- Now, Google has said all payments for any subscriptions on the apps will have to be routed only through its payment gateway from January 20, 2021.
- Prior to this, many subscription apps were either using other Google Payment Gateway or other third party services. Or they ensured that transaction was done outside the Play Store on their websites.
- Google has provided time till September, 2021, for the apps to integrate into its payment gateway.
- Indian startups are worried as 30 percent commission on the value of the transaction is very high as this will severely impact their revenue and profits.
- This will also impact other third-party payment gateway service providers like Razorpay and PayU.
- In India, a very small percentage of consumers pay for subscriptions, and startups believe this 30 percent fee will further eat into their revenue and profits.
- Now, the alternative is to create an India specific platform, but challenges are plenty in terms of quality, stability, and popularity.
- There are other app platforms like Amazon and Samsung to name a few, but these are not very popular as it is Android and iOS which have dominated the smartphone operating systems.
Don’t panic, but be positive, says Biocon’s Kiran Mazumdar Shaw on her experience with COVID-19 - YourStory
Kiran Mazumdar Shaw, Executive Chairperson – Biocon shares her personal experience with COVID-19 and advocates testing even if one experiences mild symptoms.
My first symptom was a mild feverish feeling late evening on August 16. I had felt similar symptoms in early June and I tested negative so I just took a Crocin and thought it would take care of it. The next morning though, I continued to feel feverish and I measured it - 99 F. That’s when I decided to test myself and my entire household as I have my 89-year-old mother, a cancer survivor and my 71-year-old husband, a cancer patient to worry about. I immediately self-quarantined in a separate room and waited anxiously for the test results. At 5pm I was told that I tested positive but everyone else at home including my staff tested negative. Mercifully, the virus spared my mum and my husband. I asked for the CT (Cycle Threshold) value to assess my viral load and when I saw it was 23, I felt the load was safe enough to be home quarantined under tele-supervision. Dr Murli Mohan from Narayana Health, Bengaluru and Dr Shashank Joshi from Lilavati hospital, Mumbai, were my key medical supervisors. I was put on a course of Favipiravir, azithromycin and paracetamol. Apart from this, I continued with my daily dose of Vit C, Vit D, Zinc, baby aspirin and chyavanprash! Not to mention my twice a week 200mg dose of HCQ! Day two and three were uneventful. I was measuring my oxygen saturation levels six times a day which were all between 96-98 percent even after a brisk six-minute walk. My temperature was normal but late evening on Day 3, I felt flu-like symptoms and it extended to Day 4 and 5. There was no measurable temperature but frequent bouts of sweating, which suggested that my body was fighting the virus. I was also tracking my Cytokine levels. My cRP was normal at <0.5 throughout the infected period, which indicated no inflammation. My D-Dimer and Ferritin levels were also within normal range. I also tracked my cytokine levels especially IL-6 which were undetectable. By Day 6, I started feeling better. My rtPCR test on Day 10 was still positive but with a CT value of 33 suggesting a very low and non-infectious viral load generally attributed to dead virus shedding. I also tested my blood for antibodies n T-cells on Day 9. IgM was noticeably present but not IgG. My innate immune response based on Dendritic and NK cells was strong. A robust T cell activation was observed in my sample with a higher frequency of antigen specific T cells, effector T cells, Memory T cells and cytokine release on stimulation. I basically had developed T Cell immunity which could potentially protect me for a long duration. On Day 12 My rtPCR test was positive with a CT value of 36 heralding the final leg of my Covid19 saga! My experience has been mild and uneventful. No loss of smell or taste n no drop in oxygen saturation. I recommend to everyone with mild fluish symptoms to test and decide on hospitalisation or home quarantine based on viral load: CT values <20 with fever ought not to home isolate. Monitoring oxygen saturation several times a day is psychologically good for your virus fighting morale. I also recommend that you try and exercise or go for a short walk every day to keep fit. I did not experience any loss of appetite and I suggest a diet of fruit, vegetables, lentils and cereal. Soups and salads were a daily feature for my meals. My constant companions were Netfllix and Amazon Prime; avoid TV and social media as negative news are bad for fighting Covid19!
- Don’t panic on testing positive.
- Make sure you assess your viral load based on CT value.
- Mild symptoms with moderate viral load qualify for home isolation.
- Monitor your oxygen saturation several times a day to ensure it doesn’t drop below 95%
- Make sure you are supervised by a doctor through a Telehealth program.
- Do yoga and walk as much as you can.
- Your body will fight the virus in a week.
- Doctors should not just treat clinical Symptoms but rather the cause of the symptoms. For example, if SpO2 reduces, just increasing oxygen flow is not the answer. Treating inflammation caused by cytokines is the answer.
- Lack of early intervention in mitigating the inflammation n cytokine storm can cause post COVID-19 fatigue and respiratory ailments.
- Finally, please test and present yourself as soon as you feel mild symptoms. Do not be in denial n wait for more severe symptoms. You have reduced your chances of a mild disease by doing so.
Bharat Biotech, US university tie up for COVID-19 vaccine - YourStory
Vector used in new coronavirus vaccine is a deactivated rabies vaccine known to produce a strong immune response; it has been proven safe for all populations, including children and pregnant women.
Vaccine innovator Bharat Biotech and Thomas Jefferson University of Philadelphia have signed an exclusive deal to develop a new vaccine candidate for COVID-19 invented at Jefferson. The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.This vehicle, or carrier vaccine, is known to produce a strong immune response and is approved for the entire population, including children and pregnant women. Infectious diseases expert Professor Matthias Schnell’s lab developed the vaccine in January this year. Preliminary tests on animals have been completed; the vaccine showed a strong antibody response in mice. The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection, with results expected in the next month. “Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Prof Schnell, a coronavirus expert who directs the Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology. “We will be able to complete animal testing and move to phase 1 clinical trial rapidly,” he added. Dr Krishna Mohan, Chief Executive Officer, Bharat Biotech, said, “In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, US, towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform. We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases. Bharat Biotech is committed to global public health and will be involved in end-to-end development of the vaccine, including comprehensive clinical trials to achieve commercial licensure." Under the licence agreement, Bharat Biotech gains exclusive rights to develop, market, and deliver Jefferson’s vaccine across the world, excluding countries such as the US and Japan and in Europe, where Jefferson continues to seek partners. With support from the Department of Biotechnology, Bharat Biotech aims to get into human trials as soon as December 2020. “Bharat Biotech is the world’s largest supplier of rabies vaccines, and has been at the forefront of creating breakthrough vaccines for several challenging diseases,” said D. Rose Ritts, Jefferson’s Innovation Executive Vice President, who led negotiations with the assistance of Dr Heather Rose, Innovation Vice President.“They are the right partner for Jefferson to accelerate this important project with urgency,” he added. Of the 90 or so coronavirus vaccines in development, about 25 percent use an established vaccine to act as a “carrier” or vector for the target virus, in this case, the coronavirus SARS-COV-2 spike protein. Not every vaccine produces the same level of the immune response.The rabies vaccine has been shown to generate a rigorous but safe immune reaction that confers life-long protection. “Since we know the immune system reacts to the rabies vaccine with a strong response when we add the coronavirus component, we expect to see that level of protection, and immune memory, carry over to the SARS-CoV-2 viral protein as well,” says Prof Schnell. Prof Schnell’s prior research creating vaccines with this approach against two other strains of coronavirus (the 2003 SARS and 2012 MERS viruses), worked in this way, conferring strong immunity in animal models. “We are leveraging the properties of a very effective vaccine – one that provides life-long immunity against one of the biggest global threats of our time,” said Dr Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs at Thomas Jefferson University, and Dean of its Sidney Kimmel Medical College. “Rather than go with an untested approach, we have a leg-up by using a vaccine that is safe, effective, and exceptionally good at creating a strong immune response – which is something not every vaccine can do.” How has the coronavirus outbreak disrupted your life? And how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to [email protected]